Britain expands access to Pfizer’s antiviral COVID-19 treatment through clinical trial

Paxlovid has shown to reduce the risk of death and hospitalisations by 90%.

Britain has added Pfizer’s antiviral COVID-19 treatment, Paxlovid to a clinical trail in efforts to expand the drugs access across the country. The health ministry stated that the trial will allow thousands of people access to the antiviral drug and will allow the pharmaceutical company to assess how best to use the drug in highly vaccinated people. Paxlovid is a combination of Pfizer’s newer oral treatment and ritonavir, the older antiviral. The combination drug will be made available to Britons who are immune-compromised. Sajid Javid, Britain’s health minister in a statement, "As we learn to live with COVID, the UK continues to lead the way in using cutting-edge treatments which have already saved the lives of many of the country's most vulnerable patients."

The country reported 170,000 COVID-9 deaths and Prime Minister Boris Johnson referred to antivirals as a part of the strategy to learn to live with the virus stating that the country can cut down the deaths among those who do not benefit as much from the vaccine The antiviral has shown to decrease the risk of death or hospitalisations by almost 90%. The study is open to participants aged 18 to 49 or 50 years and older, who have underling health condition that could put the at higher risk to severe COVID-19. After molnupiravir an oral drug produced by Merck & Co, Paxlovid is the second antiviral to be added to the Panoramic clinical trial. Twenty thousand participants joined the study to generate data on molnupiravir while 17,500 participants were enrolled into the Paxlovid trial.